Core Capital Management & Research, inc.’s Gilead Sciences GILD Stock Holding History

Core Capital Management & Research, inc.’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46.5K	Buy	+318	New	+$41.9K	0.02%	123

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Core Capital Management & Research, inc.'s GILD Position: Q2 2026 in Review

Core Capital Management & Research, inc. opened a new position in Gilead Sciences (GILD) in Q2 2026: 318 shares worth $46.5K. The stake represents 0.02% of the portfolio and ranks #123 among its holdings.

2,281 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Core Capital Management & Research, inc. held 318 shares of Gilead Sciences worth $46.5K as of Q2 2026.
Gilead Sciences was a new Core Capital Management & Research, inc. position in Q2 2026.
Gilead Sciences made up 0.02% of Core Capital Management & Research, inc.'s portfolio in Q2 2026, its #123 holding.
2,281 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Core Capital Management & Research, inc.'s 13F filing for Q2 2026, filed 9 Sep 2026.